This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Oct. 11, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against OvaScience, Inc ("OvaScience" or the "Company")(NASDAQ: OVAS) and certain of its officers. The class action, filed in United States District Court, District of
Massachusetts, and docketed under 13-cv-12286, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of OvaScience between
February 25, 2013 and
September 10, 2013 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
If you are a shareholder who purchased OvaScience securities during the Class Period, you have until
November 15, 2013 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at
www.pomerantzlaw.com. To discuss this action, contact
Robert S. Willoughby at
email@example.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.
OvaScience is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company's patented technology is based on the discovery of egg precursor cells (EggPC
SM), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, AUGMENT
SM aims to improve egg quality and increase the success of in vitro fertilization.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business and operations. Specifically, OvaScience represented to the FDA and investors that it believed that AUGMENT qualified for designation as a 361 HCT/P, which allows human cellular and tissue based products to be tested and marketed without FDA licensure. Yet despite this representation, OvaScience never qualified for this designation.